Skip to Content

Solid Biosciences, Inc. (SLDB)

Securities Class Action

Overview
  • Date:
  • 3/28/2018
  • Company Name:
  • Solid Biosciences, Inc.
  • Stock Symbol:
  • SLDB
  • Class Period:
  • FROM 1/22/2018 TO 3/14/2018
  • Status:
  • Closed/Complete
  • Court:
  • U.S. District Court: Massachusetts

Case Finder

Locate any case using the tools below.

NEW YORK, March 28, 2018 – Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed in the U.S. District Court for the District of Massachusetts on behalf of all persons or entities who purchased or otherwise acquired Solid Biosciences, Inc. (NASDAQ: SLDB) issued in connection with the Company’s January 25, 2018 initial public offering (“IPO”), or on the open market between January 25, 2018 and March 14, 2018 (the “Class Period”).  Investors have until May 29, 2018 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

The complaint alleges that Defendants failed to disclose: (1) that Solid Biosciences’ lead drug candidate SGT-001 had a high likelihood of causing adverse events in patients; (2) that Solid Biosciences misled investors regarding the toxicity of SGT-001; and (3) that, as a result of the foregoing, Defendants statements in the Registration Statement regarding Solid Biosciences’ business, operations, and prospects, were materially false and/or misleading.

If you purchased or otherwise acquired Solid Biosciences securities in connection with the IPO or in the Class Period and suffered a loss, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: